Therefore, measuring tumor markers such as CEA and CA 19-9—both in serum and in peritoneal fluid—may offer valuable complementary biomarkers for assessing the tumor burden, especially in cases where molecular detection falls short. This evidence concerns the gene CEACAM5 and neoplasm.